How hayfever works: The Full Evidence

Does hayfever get worse with age or do most adults see improvement over decades?

What the research says

The long-term trajectory of allergic rhinitis in adults is more often one of gradual improvement or stability than worsening, with studies reporting 20-55% remission rates and only ~9% of patients experiencing worsening over decades. Symptoms typically peak between ages 20-40, after which partial or complete remission becomes increasingly common, though 75% persistence of pollen-AR has been reported in some cohorts through early adulthood. Complete cure is relatively rare; many 'improvers' remain symptomatic or sensitized, and a substantial minority (roughly one-third) experience no meaningful change.

How it works

Persistence of allergic rhinitis is strongly driven by ongoing IgE-mediated sensitization — early and persistent allergen sensitization significantly reduces odds of remission (aOR ~0.20-0.26) by sustaining Th2-skewed immune responses and mast cell/eosinophil activation. Symptom remission can occur even without desensitization, suggesting that age-related immunological shifts (possibly declining IgE responsiveness or reduced mucosal reactivity) may uncouple sensitization from clinical expression over time.

---

Can adults develop new pollen sensitisations in their 30s, 40s, or later?

What the research says

Adults can and do develop new pollen sensitisations in their 30s, 40s, and beyond, supported by longitudinal cohort data. The Northern Finland Birth Cohort 1966 study (n>5,000) directly measured new-onset sensitisation between ages 31 and 46, confirming incident sensitisation in this middle-age window, while Italian clinical studies found that adults monosensitised to 'newer' regional allergens like ragweed and birch were substantially older at onset (mean ~35 years) than those sensitised to traditional allergens, suggesting sensitisation predisposition persists throughout adult life. Swedish population data further show that pollen sensitisation prevalence increased over two decades in adults aged 16–60, consistent with ongoing adult acquisition rather than exclusively childhood-onset disease.

How it works

New adult-onset pollen sensitisation likely reflects cumulative allergen exposure thresholds being crossed later in life, particularly for allergens newly introduced to a region, combined with pollen protease-mediated disruption of the respiratory epithelial barrier and dendritic cell activation that can initiate Th2-skewed immune responses at any age. Endotoxin exposure (e.g., farming environments) appears to suppress new-onset pollen sensitisation in adults, implicating innate immune modulation as a protective counter-mechanism.

---

What factors predict whether hayfever will escalate, stabilise, or resolve over time?

What the research says

Longitudinal studies consistently identify distinct allergic rhinitis trajectory phenotypes—persistent, decreasing, late-increasing, and minimal—with approximately 75% of childhood pollen-AR cases persisting into early adulthood and remission occurring most commonly during adolescence (approximately 21.5% between ages 16–24). Key predictors of persistence and escalation include early-onset high symptom burden, comorbid asthma or atopic dermatitis, elevated IgE and eosinophils, and family history of atopy, while later disease onset and diminishing symptoms in the first year are associated with stabilisation or remission. Immunotherapy (particularly HDM subcutaneous immunotherapy) and early intervention appear to modify the natural course, increasing the probability of clinical remission.

How it works

Persistent and escalating AR is driven by sustained Type 2 immune activation—characterised by elevated IgE, eosinophilia, upregulated nasal T2-associated transcriptomic signatures, and ongoing aeroallergen sensitisation—which perpetuates mast cell and eosinophil-mediated mucosal inflammation and lowers the threshold for bronchial involvement. Remission likely reflects developmental immunological maturation, reduced allergen sensitisation burden, or allergen-specific tolerance induction (as achieved through immunotherapy).

---

Does cumulative lifetime pollen exposure increase sensitisation and symptom severity?

What the research says

Evidence for cumulative lifetime pollen exposure driving progressive sensitisation and symptom severity is limited and indirect; most available data focus on early-life (prenatal and first-year) exposures, where dose-response associations with asthma risk have been demonstrated (e.g., joint high exposure in both periods yielding OR=8.30, 95% CI 1.68–40.94). The 2025 systematic review and meta-analysis (31 studies) and a 73-study meta-analysis on asthma exacerbations confirm acute pollen-symptom dose-response relationships, but neither directly quantifies how decades of cumulative exposure alter sensitisation trajectories or rhinitis severity. No longitudinal cohort studies tracking IgE sensitisation thresholds, polysensitisation progression, or immune tolerance breakdown across a lifespan were identified.

How it works

Early-life pollen exposure appears to prime Th2-skewed immune responses, potentially establishing sensitisation patterns that increase susceptibility to asthma and allergic disease, though the precise mechanisms by which cumulative lifetime exposure compounds or sustains this sensitisation—such as progressive IgE amplification, regulatory T-cell exhaustion, or epithelial barrier degradation—remain poorly characterised in the literature.